AccessDx Acquires 2bPrecise From Allscripts

Original from Genomeweb

AccessDx Holdings said Wednesday that it has acquired 2bPrecise, a service and technology provider that integrates genetic and genomic test results into electronic health records, from EHR giant Allscripts Healthcare Solutions for an undisclosed amount.

AccessDx, a Houston-based CAP/CLIA diagnostic laboratory and software firm, said that 2bPrecise will augment its line of molecular diagnostics, software, and services products, which already includes clinical decision support software brand MedTek21.

"We're thrilled to welcome the 2bPrecise team and platform as we execute on our combined vision for democratizing the use, interpretation, and delivery of advanced diagnostic solutions at the point of care," Joe Spinelli, senior VP of product and strategy for AccessDx, said in a statement. "Combined, our worldwide organization will be able to accelerate the pace of innovation and best serve the needs of healthcare organizations that continue to expand their adoption of actionable precision medicine solutions."

Assaf Halevy, founder and CEO of 2bPrecise, said that the combination will speed up adoption of precision medicine within healthcare organizations. "AccessDx is a genuine leader in genomic information management. Our collective capabilities will serve as a force … for the practical utilization of precision medicine," he said.

Israel-based 2bPrecise was founded in 2015 with Allscripts as its primary investor. The EHR vendor eventually purchased the startup in its entirety.

2bPrecise integrates genetic and genomic data from molecular labs with clinical information from EHRs into a clinical-genomic ontology for use by physicians. It has a relationship with EHR integration specialist Jase Health, a company that AccessDx forged a partnership with earlier this year.

Source: AccessDx Acquires 2bPrecise From Allscripts | Genomeweb